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morning. The Rhinoconjunctivitis Quality of Life Ques-
tionnaire (RQLQ) created by Juniper and Guyatt was
transformed on to a digital optical character reading data
collection form. Patients completed the questionnaire at
baseline, week 1, and week 3. Statistical significance was
determined by the paired samples t test, and clinical sig-
nificance was determined by a previously set standard of
a 0.5 point change in the RQLQ score. 
RESULTS: The mean RQLQ score at base line was 2.75
(N  25, SD  1.08). The mean RQLQ score at the end
of week 3 was 1.26 (N  25, SD  .86). The mean score
improvement on the RQLQ was 1.49 points (lower
RQLQ score means better QOL). The improvement in
quality of life was both statistically (t  5.21; df  24;
p  0.001) and clinically significant. 
CONCLUSION: Loratadine 10 mg once a day improves
the quality of an allergic rhinitis patient’s life when used
for at least 3 weeks.
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DETERMINING THE CLINICAL RELEVANCE OF 
STATISTICALLY SIGNIFICANT IMPROVEMENTS 
IN QUALITY OF LIFE
Schleusener D, Coen M, Thompson A
Hoechst Marion Roussel, Kansas City, MO, USA
OBJECTIVE: The purpose of this research was to deter-
mine the clinical relevance of an observed statistical im-
provement. 
METHODS: A randomized controlled trial was per-
formed to compare once daily fexofenadine HCl (120 mg
and 180 mg combined, n  559) to placebo (n  286) in
patients with seasonal allergic rhinitis. The Rhinitis Qual-
ity of Life Questionnaire (RQLQ), assessing quality of life
in the areas of activities, sleep, miscellaneous symptoms,
practical problems, nasal symptoms, eye symptoms and
emotions, was administered at baseline and 1 and 2 weeks
post-treatment. Mean change from baseline differences be-
tween treatments, averaged over weeks 1 and 2, were ana-
lyzed as the most powerful test of treatment differences.
However, it has been shown that a within-patient change
of 0.5 on the 7-point scale of the RQLQ is the minimum
difference of clinical relevance (Juniper et al., 1996). This
within-patient change was used to interpret statistically
significant mean differences. 
RESULTS: Patients receiving fexofenadine HCl showed
statistically significant mean improvements in total rhini-
tis related quality of life over patients receiving placebo
(mean  SE  0.39  0.05, 0.60  0.03 for placebo
and fexofenadine HCl patients respectively; p  0.0002).
The proportion of fexofenadine HCl patients who
showed a minimal clinically significant improvement of
0.5 or greater was also higher than patients receiving pla-
cebo (p  0.38, 0.48 for placebo and fexofenadine HCl
patients respectively, p  0.0045). 
CONCLUSIONS: In this study, a statistically significant
improvement in total rhinitis-related quality of life for
patients receiving once daily (120 mg and 180 mg) fex-
ofenadine HCl was also clinically relevant.
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OBJECTIVE: The study purpose was to develop an in-
strument to assess patient comfort and satisfaction with
prescribed nasal sprays in the treatment of seasonal aller-
gic rhinitis. 
METHODS: Standard instrument development method-
ology was utilized. A list of pertinent items obtained
from the literature was formulated. Each Nasal Comfort
Index (NCI) draft was scrutinized by experts regarding
item appropriateness, wording and anchor labels. Five-
point Likert scales were utilized. The NCI was organized
into pre-defined categories. Questions were included to
establish perceived importance of each category in order
to develop weights for determining a total score. Percep-
tion of content was assessed by 19 subjects. Qualitative
and quantitative data were collected. Item combination/
reduction was conducted after pre-test of the instrument.
Correlations between domain and total scores were cal-
culated to determine the best of four potential methods
for calculating these scores. 
RESULTS: Literature review revealed no existing vali-
dated methods for assessing patient comfort, satisfaction
and preferences in the target population. The final selec-
tion of items was based on qualitative and quantitative
analysis. The resultant NCI contained 20 items which,
through factor analysis, resulted in four domains explain-
ing 82% of the variance. The most appropriate scoring
method was deemed to be weighted means. 
CONCLUSIONS: Quantitative analysis confirmed many
qualitative findings. A single total score, combining the
domain scores, was considered the most clinically rele-
vant method for differentiating the effects of nasal
sprays. Validation analysis will occur on data gathered
through NCI implementation in a clinical trial.
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An economic evaluation has been performed, analyzing
direct medical costs for the treatment of perennial allergic
rhinitis (PAR) with budesonide aqueous nasal spray and
fluticasone propionate nasal spray in Canada.
BACKGROUND: In this study, 314 patients, with at
least a 1-year history of PAR, were randomized into a
double-blind, parallel group study of 6 weeks duration.
The treatments were budesonide 256 g, fluticasone pro-
pionate 200 g, or placebo. Budesonide was significantly
more effective than fluticasone in reducing “blocked
nose.” Both active treatments produced significantly lower
mean scores for overall nasal symptoms compared with
placebo, and both were well tolerated. 
METHOD: A cost-minimization analysis, utilizing the clin-
ical trial data, was performed of the total costs of 1) budes-
onide-based and 2) fluticasone-based treatment strategies,
including the relative importance of the drug cost in both
strategies. 
RESULTS: In Canada, the average treatment cost per pa-
tient over 12 months in the budesonide group was CAN$
389.85 which was 23.3% lower than in the fluticasone
group, CAN$ 508.06, due to lower drug acquisition
costs. Drug costs represented between 24.6% and 42.1%
of total treatment costs for the budesonide and the fluti-
casone group, respectively. 
CONCLUSION: Budesonide aqueous nasal spray is a
cost-effective strategy in the treatment of perennial aller-
gic rhinitis.
ECONOMIC AND OUTCOMES ISSUES OF 
INFECTIOUS DISEASE
PID1
COST-EFFECTIVENESS ANALYSIS OF 
RECOMBINANT HUMAN ERYTHROPOIETIN 
VERSUS TRANSFUSION IN HIV PATIENTS 
TREATED WITH ZIDOVUDINE
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OBJECTIVE: The purpose of this study was to determine
the cost-effectiveness of erythropoietin against transfu-
sion in HIV patients treated with zidovudine from the so-
cietal perspective. 
METHOD: Cost-effectiveness was measured based on
probability of response to dose. The cost of drug with
and without the patient drug expenditure cap under the
Manufacturers’ Patient Assistance Program was consid-
ered. Measured were incremental cost per unit of blood
spared and incremental cost per QALY. Sensitivity analy-
sis was performed on all variables in the base case. 
RESULTS: Without the drug expenditure cap, the incre-
mental cost per unit of blood spared was $577.93
($160.34 with the cap). The incremental cost per QALY
without the cap was $118,620.13 and $32,909.71 with
the cap. The cost per unit of blood with the cap was 28%
below the cost of a unit of blood (PRBC). The break-even
cost of the drug was 77% below the current cost. A plot
of the cap against the cost per unit of blood spared
yielded a straight line. The cost per unit of blood spared
became zero at $4363.25 and became equal to the cost of
a unit of blood at $10,145. 
CONCLUSION: With the cost cap, erythropoietin can
be justified by incremental cost per QALY and on its
blood sparing and cost saving effects. The drug is most
cost-effective when it obviates the need for transfusion
entirely while it cannot be justified in patients who would
otherwise require 3 units of blood or less per month.
Variations in the cost of transfused blood units impact
cost-effectiveness but remain within acceptable limits for
typically cited values.
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INCREASED COST OF MANAGING AIDS IN THE 
LAST YEAR OF LIFE
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It is possible with highly active antiretroviral therapy
(HAART) to retard progression from the HIV positive
state to AIDS. In developing an economic model of
HAART, annual costs associated with managing HIV
positive or symptomatic patients, and those with AIDS
were estimated. This presentation will focus on one as-
pect of this complex cost profile: the difference in the
management costs in a year where the AIDS patient sur-
vives versus the last year of life. 
OBJECTIVE: To estimate the difference in cost of AIDS
management between the last year of life and preceding
years. 
METHODS: Annual cost estimates include acute and sub-
acute inpatient care, outpatient care (excluding medica-
tions), emergency room, home care, hospice, counseling
and social services. Patient level data from the Massachu-
setts all payer discharge database allowed examination of
inpatient admissions for a cohort (n  340) of AIDS pa-
tients over 3 years (1994–1996). Patterns of inpatient care
for those discharged alive versus those who died in 1996
who also had admissions in 1994 and 1995 were con-
trasted. Additional 1996 data from 49,000 AIDS dis-
charges from six states were used to estimate inpatient
costs. These sources were supplemented by fee schedules,
other agency data and the literature. Costs are reported in
1998 US dollars, adjusted for medical inflation and cost-
to-charge ratios. 
RESULTS: The mean annual cost of acute inpatient care
is 36% higher in the last year of life ($31,302) than in
preceding years ($27,520). Inclusion of other resource
use increases the difference in management costs almost
three-fold ($18,289 versus $6,540). 
